Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00001547 · ClinicalTrials.gov registry record

Neuropsychiatric Effects of Interferon-Alpha and Ribavirin

A clinical trial of Mental Disorder, sponsored by National Institute of Mental Health (NIMH).

Completed
Registry status
150
Enrollment target
1
Study location

NCT00001547: Completed study of Mental Disorder, sponsored by National Institute of Mental Health (NIMH).

NCT00001547 is a study of Mental Disorder that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 150 participants, below the 318-participant average among 21 other Mental Disorder trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00001547, a study of Mental Disorder, has completed, sponsored by National Institute of Mental Health (NIMH).

COMPLETED
Registry status
150 participants
Enrollment target
1
Study location

Study Summary

Use of the drug interferon-alpha (IFN-A), is associated with frequent and well characterized side effects like neurotoxicity. Neurotoxicity can cause symptoms of depression, agitation, anxiety, and/or confusion. The NIDDK is conducting a research study called, "Combination of Alpha Interferon with Long Term Ribavirin Therapy for Patients with Chronic Hepatitis C" (98-DK-0003). Patients participating in it are receiving interferon-alpha in addition to an antiviral medication called ribavirin. Researchers at the NIMH intend to study patients to learn more about how different medications can influence mood, thoughts and behavior. The primary purpose of this study is to determine if treatment with IFN-A in combination with ribavirin alters human brain biochemistry as measured by proton magnetic resonance spectroscopy (MRS). MRS uses strong magnetic fields in order to measure biochemical products of metabolism found in the brain. Researchers intend to perform MRS scans before, during, and after patients receive their medications Researchers believe that the combination of IFN-A/Ribavirin will directly affect specific areas of the brain and as a result, some patients will develop specific mood or cognitive symptoms. Patients often must stop taking these medications because of the side effects. This study will not contribute directly to the treatment of patient's Hepatitis C condition. However, the information gathered from this study will help researchers better understand the neuropsychiatric affects associated with interferon alpha and ribavirin therapy.

Conditions Studied

Study Locations (1)

Maryland

  • National Institute of Mental Health (NIMH) - Bethesda

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 1996-06
Est. Completion 2002-06

What the finished NCT00001547 record still lists

NCT00001547 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 318-participant average among 21 other Mental Disorder trials with a reported enrollment target (53% lower).

The record links to 1 condition, with Mental Disorder appearing as the primary indexed condition, and to 0 interventions.

NCT00001547 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT00001547 about?

NCT00001547 is a clinical study titled "Neuropsychiatric Effects of Interferon-Alpha and Ribavirin". Use of the drug interferon-alpha (IFN-A), is associated with frequent and well characterized side effects like neurotoxicity. Neurotoxicity can cause symptoms of depression, agitation, anxiety, and/or confusion. The NIDDK is conducting a research study called, "Combination of Alpha Interferon with ...

What is the current status of trial NCT00001547?

This trial is currently completed. The enrollment target is 150 participants. The study started on 1996-06. Estimated completion is 2002-06.

What conditions does trial NCT00001547 study?

This clinical trial studies the following conditions: Mental Disorder.

Who is sponsoring clinical trial NCT00001547?

This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00001547 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Mental Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00001547's enrollment target sits among peer trials

150 10th of 21 higher than 11 of 21 other Mental Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Mental Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00412594 · 150 participants · Phase 2

    Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

  • NCT01484730 · 150 participants

    A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion

  • NCT01985919 · 150 participants

    Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

  • NCT02016248 · 150 participants · NA

    SBRT Boost for Unfavorable Prostate Cancer'

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00001547, the US trial registry maintained by the National Library of Medicine. NCT00001547 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.